Congenital Adrenal Hyperplasia

Richard J.M. Ross, MD, FRCP, professor of endocrinology in the department of oncology and metabolism at the University of Sheffield in the United Kingdom, has taken a different career path than most in his field.

Adults with congenital adrenal hyperplasia who received an oral corticotropin-releasing hormone antagonist for 14 days experienced significant reductions in androgen levels with no serious adverse events, study data show.

Children and adolescents with congenital adrenal hyperplasia, or CAH, diagnosed early via a neonatal screening program and treated with hydrocortisone had normal psychometric intelligence and executive function compared with population controls, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Higher glucocorticoid doses for adults with congenital adrenal hyperplasia may be associated with lower bone mineral density, especially among women and those prescribed prednisolone, according to findings published in Clinical Endocrinology.

Adults with classic congenital adrenal hyperplasia who received a once-daily, nonsteroidal oral therapy for 12 weeks experienced significant reductions in androgen levels with no serious adverse events, according to findings from a phase 2a study.